Quantcast

Latest MedImmune Inc. Stories

2010-07-20 08:15:00

MENLO PARK, Calif., July 20 /PRNewswire/ -- 3-V Biosciences, Inc. today announced the appointment of James F. Young, Ph.D. to its Board of Directors. "We are very pleased to welcome Jim Young to the 3-V Board," said David M. Mott, 3-V's Executive Chairman. "Jim's expertise as a virologist, immunologist, drug developer and company builder make him extraordinarily well suited to assist 3-V in its mission to build the leading host cell factor anti-infective company. Jim has a great nose...

2010-06-03 08:15:00

MENLO PARK, Calif., June 3 /PRNewswire/ -- 3-V Biosciences, Inc. announced today the appointment of Edward M. Connor, Jr., MD, as Chief Medical Officer. "Ed Connor is among the most experienced respiratory infectious disease drug developers in the world, having led the development of RespiGam and Synagis® for respiratory syncytial virus and FluMist® for influenza," said David M. Mott, 3-V's Executive Chairman. "He has further extensive experience in...

2010-04-19 11:00:00

ATLANTA, April 19 /PRNewswire/ -- MedImmune announced today it will present 10 abstracts at the National Immunization Conference (NIC), all of which add to the company's growing body of research regarding pediatric infectious disease prevention. "With the growing importance of influenza prevention, it is essential to better understand the current data on influenza vaccines as well as how best to provide them to children and adults in the United States," said Alexander A. Zukiwski, M.D.,...

2009-10-30 10:56:00

PHILADELPHIA, Oct. 30 /PRNewswire/ -- MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 29 through November 1, 2009. These abstracts advance the body of data surrounding respiratory syncytial virus (RSV) and influenza prevention, highlighting MedImmune's leadership in pediatric health. "MedImmune is dedicated to conducting ground-breaking research on the prevention of respiratory...

2009-07-30 15:02:00

INCLINE VILLAGE, Nev., July 30 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the second quarter ended June 30, 2009. Total revenues from continuing operations for the second quarter of 2009 were $125.9 million, an 18 percent increase from $106.5 million for the same period in 2008. The increase was due primarily to royalty revenues driven by higher product sales of Avastin(R), and Lucentis(R), which are marketed by Genentech,...

2008-10-29 09:00:36

PLYMOUTH MEETING, Pa., Oct. 29 /PRNewswire-FirstCall/ -- Genaera Corporation today reported that development partner MedImmune, Inc. presented interim Phase 2a data on MEDI-528, its monoclonal antibody (MAb) targeting interleukin-9 (IL-9) in adults with mild, persistent asthma, at The American College of Chest Physicians meeting held October 25-30 in Philadelphia, Pennsylvania. The presentation, entitled "Multiple Subcutaneous Doses of MEDI-528, A Monoclonal Antibody Against Interleukin-9...

2008-10-01 15:00:50

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. World Intranasal Drug Delivery Market http://www.reportlinker.com/p092577/World-Intranasal-Drug-Delivery-Market.html This report analyzes the US market for Intranasal Drug Delivery in US$ Million. The product is analyzed by the following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Annual forecasts are provided...

2008-09-18 06:00:19

Reportlinker.com announces that a new market research report related to the Infectious diseases industry is available in its catalogue. World Human Vaccines Market http://www.reportlinker.com/p092575/World-Human-Vaccines-Market.html This report analyzes the worldwide markets for Human Vaccines in Millions of US$. The major product segments analyzed are Prophylactic Vaccines (Pediatric Prophylactic Vaccines, & Adult Prophylactic Vaccines), and Therapeutic Vaccines. The report...

2008-08-14 15:00:18

BETHESDA, Md., Aug. 14 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced publication of a Phase 1 clinical study(1) on its BiTE(R) antibody blinatumomab (MT103/MEDI-538) in this week's issue of Science. The article is available at http://www.sciencemag.org/. Blinatumomab is being co-developed with MedImmune. Blinatumomab is a novel antibody...

2008-08-12 12:00:34

PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R). Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount. The Phase 2A clinical trial is...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related